Ajooni Biotech Ltd
NSE: AJOONI BSE: 535040
₹4.05
(-1.46%)
Sat, 11 Apr 2026, 01:49 pm
Market Cap664.86M
PE Ratio14.98
Dividend0
Miscellaneous
Miscellaneous
24.5KAjooni Biotech Analysis
dividend
- Unable to evaluate Ajooni Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Ajooni Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Ajooni Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Ajooni Biotech is profitable, therefore cash runway is not a concern.
- Ajooni Biotech is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 6.2x debt.
- Ajooni Biotech's cash and other short term assets cover its long term commitments.
- Ajooni Biotech's level of debt (19.2%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- Interest payments on debt are not well covered by earnings (EBIT is 2.8x annual interest expense, ideally 3x coverage).
- High level of physical assets or inventory.
management
- Jasjot's remuneration is lower than average for companies of similar size in India.
- The average tenure for the Ajooni Biotech board of directors is less than 3 years, this suggests a new board.
- Jasjot's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
misc
- Ajooni Biotech is not covered by any analysts.
- Ajooni Biotech's last earnings update was 216 days ago.
- Ajooni Biotech has significant price volatility in the past 3 months.
past
- Ajooni Biotech has delivered over 20% year on year earnings growth in the past 5 years.
- Ajooni Biotech's 1-year earnings growth is less than its 5-year average (3% vs 28.5%)
- Ajooni Biotech used its assets less efficiently than the IN Food industry average last year based on Return on Assets.
- Ajooni Biotech's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Ajooni Biotech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Ajooni Biotech's earnings growth has not exceeded the IN Food industry average in the past year (3% vs 20.5%).
value
- Ajooni Biotech is good value based on assets compared to the IN Food industry average.
- Ajooni Biotech is good value based on earnings compared to the IN Food industry average.
- NSEI:AJOONI is up 14.3% outperforming the Food industry which returned 5% over the past month.
- NSEI:AJOONI is up 14.3% outperforming the market in India which returned 8% over the past month.
- Ajooni Biotech is overvalued based on earnings compared to the India market.
- AJOONI underperformed the Food industry which returned 18.8% over the past year.
- AJOONI underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800